Rubius Therapeutics to Announce First Quarter 2020 Financial Results
May 04 2020 - 4:01PM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced plans to report first quarter 2020 financial results
on Monday, May 11, 2020, before market open.
The company will not be conducting a teleconference in
conjunction with its financial results press release.
About Rubius Therapeutics Rubius
Therapeutics is a clinical-stage biopharmaceutical company
developing a new class of medicines called Red Cell Therapeutics™.
The Company’s proprietary RED PLATFORM® was designed to
genetically engineer and culture Red Cell Therapeutics™ that are
selective, potent and off-the-shelf allogeneic cellular therapies
for the potential treatment of several diseases across multiple
therapeutic areas. Rubius’ initial focus is to advance RCT™ product
candidates for the treatment of cancer and autoimmune diseases by
leveraging two distinct therapeutic modalities — potent cell-cell
interaction and tolerance induction. For more information,
visit www.rubiustx.com, follow us on Twitter or LinkedIn or
like us on Facebook.
Contacts:Lori Melançon Vice President,
Corporate Communications and Investor Relations +1 (617) 949-5296
lori.melancon@rubiustx.com
Media Contact: Dan Budwick 1AB +1 (973)
271-6085 dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024